NCR Online Journal

Gene and Cell Therapies in Rare Disorder Market Trends Analysis, Growth Opportunities and Challenges, Clinical Activities, Leading Companies, Emerging Therapies, and Epidemiology Forecast

 Breaking News
  • No posts were found

Gene and Cell Therapies in Rare Disorder Market Trends Analysis, Growth Opportunities and Challenges, Clinical Activities, Leading Companies, Emerging Therapies, and Epidemiology Forecast

June 23
20:37 2022
Gene and Cell Therapies in Rare Disorder Market Trends Analysis, Growth Opportunities and Challenges, Clinical Activities, Leading Companies, Emerging Therapies, and Epidemiology Forecast
DelveInsight’s “Gene and Cell Therapies in Rare Disorder Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gene and Cell Therapies in Rare Disorder, historical and forecasted epidemiology as well as the Gene and Cell Therapies in Rare Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Gene and Cell Therapies in Rare Disorder Market Insights, Epidemiology, and Market Forecast-2032”.

 

DelveInsight’s “Gene and Cell Therapies in Rare Disorder Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gene and Cell Therapies in Rare Disorder, historical and forecasted epidemiology as well as the Gene and Cell Therapies in Rare Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

 

Some of the key facts of the Gene and Cell Therapies in Rare Disorder Market Report:

  • The total market size of Gene Therapies targeting Rare Diseases was USD 6 Billion in 2021
  • The United States accounts for the highest market size of Gene Therapies targeting Rare Diseases, followed by EU5 in the market in 2021
  • The market size of Gene Therapies is expected to grow with a significant CAGR in the upcoming years

 

Request a sample for the Report: https://www.delveinsight.com/sample-request/gene-and-cell-therapies-in-rare-disorder-market

 

Key benefits of the report:

  1. Gene and Cell Therapies in Rare Disorder market report covers a descriptive overview and comprehensive insight of the Gene and Cell Therapies in Rare Disorder Epidemiology and Gene and Cell Therapies in Rare Disorder  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Gene and Cell Therapies in Rare Disorder market report provides insights on the current and emerging therapies.
  3. Gene and Cell Therapies in Rare Disorder market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Gene and Cell Therapies in Rare Disorder market report offer an edge that will help in developing business strategies by understanding trends shaping and driving the Gene and Cell Therapies in the Rare Disorder market. 

 

Got queries? Click here to know more about the Gene and Cell Therapies in the Rare Disorder Market Landscape 

 

Gene and Cell Therapies in Rare Disorder Overview: 

As per the World Health Organization (WHO) (n.d.), there may be about 5000–8000 identified rare diseases across the globe. Yet, only a few hundred have treatment approved. The majority of uncommon diseases are known to have hereditary causes, although many others, such as infections, some rare malignancies, and some autoimmune diseases, do not run in families. Even though scientists learn more every year, it’s still unclear what exactly causes many rare disorders. 

Academic research has been a key, and frequently the only, factor behind the dramatic advancement of gene transfer technologies for the treatment of uncommon genetic illnesses over the past two decades. Investors and companies have now begun to take notice thanks to a number of groundbreaking clinical trials that demonstrated the effectiveness and safety of last-generation technology and to favorable orphan drug regulations in both Europe and the United States.

 

Gene and Cell Therapies in Rare Disorder Market  

The dynamics of the Gene and Cell Therapies in Rare Disorder treatment market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as SB-525 + ST-920, RGX-314,   and others during the forecasted period 2019-2032. 

 

Learn more by requesting for sample @Gene and Cell Therapies in Rare Disorder Market Landscape 

 

Currently Approved Gene Therapy option for Rare Disease (Non-Exhaustive): 

Zolgensma (Novartis)- Injection-Approved in 2019 

Zolgensma (onasemnogene abeparvovec-xioi) is a gene replacement therapy that was developed for the treatment of spinal muscular atrophy (SMA) in pediatric patients. Originally the therapy was developed by Avexis, the drug became a part of Novartis’s portfolio after it acquired Avexis in May 2018.

The treatment is recognized as a European priority medicine (PRIME) and a breakthrough therapy by the FDA. The European Medicines Agency (EMA) assessed it for approval in the EU as part of an accelerated evaluation process. The SAKIGAKE title was given to the organization by the Japanese Ministry of Health, Labour, and Welfare (MHLW). SMA type 1 is treated with the medication zolgensma. In 2020, it was approved by the European Union and Japan.

 

Spinraza (nusinersen)-Injection-Approved in 2016

Antisense oligonucleotide (ASO) Spinraza is intended to treat spinal muscular atrophy (SMA), which is brought on by mutations in chromosome 5q that result in SMN protein shortage. To promote the synthesis of full-length SMN protein, SPINRAZA modifies the splicing of the SMN2 pre-mRNA. ASOs are brief synthetic nucleotide strings created to regulate gene expression by binding specifically to target RNA. Through the application of this technology, SPINRAZA may help SMA patients produce more full-length SMN protein. 

Intrathecal injections of SPINRAZA are used to administer the medication, which distributes treatments directly to the cerebrospinal fluid. (CSF) surrounding the spinal cord, where motor neurons deteriorate in SMA sufferers as a result of inadequate SMN protein concentrations. 12 mg (5 mL) of the prescribed dosage should be administered each time. 

The European Medicines Agency approved SPINRAZA as a treatment for SMA in October 2016, and the EMA’s Committee for Medicinal Products for Human Use (CHMP) granted Accelerated Assessment status. 

 

Gene and Cell Therapies in Rare Disorder Pipeline Therapies:

  • RGX-314
  • SB-525 + ST-920
  • LB-001

 

Gene and Cell Therapies in Rare Disorder Pipeline Key Companies:

  • Sangamo Therapeutics 
  • RegenXbio
  • LogicBio Therapeutics 

 

Table of Contents

1. Gene and Cell Therapies in Rare Disorder Market Report Introduction

2. Executive Summary

3. SWOT analysis

4. Gene and Cell Therapies in Rare Disorder Patient Share (%) Overview at a Glance

5. Gene and Cell Therapies in Rare Disorder Market Overview at a Glance

6. Gene and Cell Therapies in Rare Disorder Disease Background and Overview

7. Gene and Cell Therapies in Rare Disorder Epidemiology and Patient Population

8. Country-Specific Patient Population of Gene and Cell Therapies in Rare Disorder 

9. Gene and Cell Therapies in Rare Disorder Current Treatment and Medical Practices

10. Gene and Cell Therapies in Rare Disorder Unmet Needs

11. Gene and Cell Therapies in Rare Disorder Emerging Therapies

12. Gene and Cell Therapies in Rare Disorder Market Outlook

13. Country-Wise Gene and Cell Therapies in Rare Disorder Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Gene and Cell Therapies in Rare Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight 

 

Click here to read more about Gene and Cell Therapies in Rare Disorder Market Outlook 2032

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

Related Articles